NCT04810078 2025-10-09CheckMate-67TBristol-Myers SquibbPhase 3 Active not recruiting681 enrolled 1 FDA
NCT03141177 2025-06-06CheckMate 9ERBristol-Myers SquibbPhase 3 Active not recruiting701 enrolled 17 charts 1 FDA
NCT04195750 2025-04-29A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)Merck Sharp & Dohme LLCPhase 3 Active not recruiting755 enrolled 28 charts 1 FDA
NCT03212404 2025-02-03Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersCheckpoint Therapeutics, Inc.Phase 1 Active not recruiting272 enrolled 1 FDA